Literature DB >> 8319325

Prognostic value and physiological correlates of heart rate variability in chronic severe mitral regurgitation.

K M Stein1, J S Borer, C Hochreiter, P M Okin, E M Herrold, R B Devereux, P Kligfield.   

Abstract

BACKGROUND: A variety of measures of heart rate variability have been devised to measure high-frequency (0.15-0.40 Hz), low-frequency (0.04-0.15 Hz), or ultralow-frequency (< 0.0033 Hz) fluctuations in sinus cycle length. Although measures of low-frequency and ultralow-frequency heart rate variability have been shown to correlate with prognosis in several populations with ischemic heart disease, their relevance to patients with primary valvular heart disease remains to be determined. METHODS AND
RESULTS: Thirty-eight patients with nonischemic causes of chronic severe mitral regurgitation who were in sinus rhythm underwent 24-hour ambulatory electrocardiography as part of a prospective study of the natural history of regurgitant valvular heart disease. Patients were followed for as long as 9.2 years, and end points of mortality, progression to mitral valve surgery, and development of chronic atrial fibrillation were tabulated. Time- and frequency-domain measurements of high-frequency, low-frequency, and ultralow-frequency heart rate variability were computed and compared with resting ventricular function by radionuclide cineangiography and outcome. The standard deviation of the 5-minute mean RR intervals (SDANN), a measure of ultralow-frequency heart rate variability, was correlated with left ventricular ejection fraction (r = 0.49, p = 0.002) and right ventricular ejection fraction (r = 0.43, p = 0.007), whereas low-frequency and high-frequency heart rate variabilities were not. Heart rate, ultralow-frequency heart rate variability, and, to a lesser extent, high-frequency heart rate variability exhibited significant diurnal variation, but low-frequency heart rate variability did not. Heart rate and ultralow-frequency, low-frequency, and combined low- and high-frequency heart rate variability predicted mortality and total events. The most powerful predictor of subsequent events was SDANN: Patients with reduced SDANN were significantly more likely to develop end-point events (p < 0.001) with increased progression to mitral valve surgery (p < 0.001) as well as increased early mortality (p = 0.02). In a multivariate proportional hazards model, SDANN retained independent predictive power (p = 0.001). Likewise, SDANN was the only variable that was significantly associated with the subsequent development of atrial fibrillation (relative risk, 3.1; p = 0.03).
CONCLUSIONS: Ultralow-frequency heart rate variability, as measured by SDANN, correlates with right and left ventricular performance and predicts development of atrial fibrillation, mortality, and progression to valve surgery in patients with chronic severe mitral regurgitation.

Entities:  

Mesh:

Year:  1993        PMID: 8319325     DOI: 10.1161/01.cir.88.1.127

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

1.  Effect of immersion, submersion, and scuba diving on heart rate variability.

Authors:  J D Schipke; M Pelzer
Journal:  Br J Sports Med       Date:  2001-06       Impact factor: 13.800

2.  Quantitation of mitral regurgitation after percutaneous MitraClip repair: comparison of Doppler echocardiography and cardiac magnetic resonance imaging.

Authors:  Christian Hamilton-Craig; Wendy Strugnell; Niranjan Gaikwad; Matthew Ischenko; Vicki Speranza; Jonathan Chan; Johanne Neill; David Platts; Gregory M Scalia; Darryl J Burstow; Darren L Walters
Journal:  Ann Cardiothorac Surg       Date:  2015-07

3.  Heart rate variability and clinical cardiology.

Authors:  M Malik; A J Camm
Journal:  Br Heart J       Date:  1994-01

4.  Correlation of heart rate variability with cardiac functional and metabolic variables in cyclists with training induced left ventricular hypertrophy.

Authors:  B M Pluim; C A Swenne; A H Zwinderman; A C Maan; A van der Laarse; J Doornbos; E E Van der Wall
Journal:  Heart       Date:  1999-06       Impact factor: 5.994

5.  Delayed improvement of autonomic nervous abnormality after the Maze procedure: time and frequency domain analysis of heart rate variability using 24 hour Holter monitoring.

Authors:  K Fukushima; T Emori; W Shimizu; T Kurita; N Aihara; Y Kosakai; F Isobe; K Shimomura; Y Kawashima; T Ohe
Journal:  Heart       Date:  1997-11       Impact factor: 5.994

6.  Comparison of [123I]metaiodobenzylguanidine kinetics with heart rate variability and plasma norepinephrine level.

Authors:  C Kurata; S Shouda; T Mikami; Y Wakabayashi; T Nakano; T Sugiyama; K Tawarahara; K Sakata
Journal:  J Nucl Cardiol       Date:  1997 Nov-Dec       Impact factor: 5.952

7.  The genetic contribution to heart rate and heart rate variability in quiescent mice.

Authors:  Reuben Howden; Eric Liu; Laura Miller-DeGraff; Heather L Keener; Christopher Walker; James A Clark; Page H Myers; D Clay Rouse; Tim Wiltshire; Steven R Kleeberger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

8.  Reduced diurnal variation of heart rate is associated with increased plasma B-type natriuretic peptide level in patients with atrial fibrillation.

Authors:  Shigeshi Kamikawa; Toru Miyoshi; Masayuki Doi; Naoko Orita; Mutsuko Sangawa; Takaaki Nakatsu; Youko Noguchi; Satoshi Hirohata; Shozo Kusachi; Kazufumi Nakamura; Hiroshi Ito
Journal:  Clin Cardiol       Date:  2013-04-12       Impact factor: 2.882

9.  ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats.

Authors:  Carole Muller; Kamal Yassin; Luo-Sheng Li; Magnus Palmblad; Suad Efendic; Per-Olof Berggren; Anthony Cerami; Michael Brines; Claes-Göran Östenson
Journal:  Mol Med       Date:  2015-12-29       Impact factor: 6.354

10.  Mechanism of hypotensive transients associated with abrupt bradycardias in conscious rabbits.

Authors:  Robert S Sheldon; Christopher I Wright; Henry J Duff; Ela Thakore; Anne M Gillis; Daniel E Roach
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.